Anika Therapeutics (ANIK) Change in Receivables (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Change in Receivables data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Change in Receivables rose 171.85% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 273.13% increase from a year earlier, with the FY2025 full-year figure at -$408000.0, up 87.88% from the prior year.
• Change in Receivables for Q1 2026 stood at $2.2 million, up from $1.5 million in the prior quarter.
• Over the last five years, Change in Receivables for ANIK reached as high as $6.2 million in Q2 2023 and fell as low as -$4.8 million in Q3 2024.
• Historically, Change in Receivables has averaged $314176.5 across 5 years, with a median of $1.1 million in 2023.
• Across the five-year window, Change in Receivables sank 959.27% in 2023 and soared 196.38% in 2024, its largest moves.
• Year by year, Change in Receivables stood at $647000.0 in 2022, then jumped by 70.63% to $1.1 million in 2023, then surged by 196.38% to $3.3 million in 2024, then slumped by 52.78% to $1.5 million in 2025, then soared by 41.1% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $2.2 million in Q1 2026, $1.5 million in Q4 2025, and -$1.3 million in Q3 2025.